Patient characteristics and outcomes stratified by response status at end of study
| Pt. no. . | Sex . | Age, y . | Race . | Months from Dx . | Lines of treatment, n . | Months on study . | Obs/Pom . | Remission from end of study, mo . | Relapse . | PD-L1* . | Therapy for PD . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| sCR | |||||||||||
| 1 | M | 66 | W | 38 | 3 (+ASCT) | 29 | Obs | 18+ | Strong | ||
| 2 | M | 63 | W | 56 | 3 (+ASCT) | 21 | Obs | 18+ | N/A | ||
| 3 | F | 57 | AA | 47 | 3 | 14 | Pom | 18+ | N/A | ||
| 4 | F | 57 | AA | 23 | 2 | 21 | Pom | 10 | Yes | Weak | Dara/Carf/Dex (PR, 8 mo), 2nd relapse—BCMA antibody conjugate |
| VGPR | |||||||||||
| 1 | M | 66 | AA | 145 | 4 | 27 | Pom | 18+ | Strong | ||
| 2 | F | 35 | AA | 60 | 3 (+ASCT) | 17 | Pom | 18+ | Weak | ||
| 3 | M | 50 | H | 80 | 3 (+ASCT) | 15 | Pom | 18+ | Intermed. | ||
| 4 | F | 83 | W | 307 | 4 (+ASCT) | 17 | Pom | 12 | Yes | Strong | Dara/Dex (VGPR 6, mo+) |
| 5 | F | 56 | AA | 35 | 3 | 30 | Pom | 1 | Yes | Strong | Dara/Pom/Dex (VGPR, 17 mo+) |
| PR | |||||||||||
| 1 | M | 67 | AA | 35 | 2 | 25 | Obs | 17+ | Intermed. | ||
| 2 | M | 60 | W | 42 | 2 (+ASCT) | 15 | Pom | 16 | Yes | Weak | Venetoclax/Dex (PR, 2 mo+) |
| 3 | M | 66 | W | 25 | 2 (+ASCT) | 12 | Obs | 6 | Yes | N/A | Dara/Len/Dex (PR,12 mo+) |
| Off study† | |||||||||||
| 1 | F | 65 | AA | 38 | 2 | 20 (sCR) | Obs | 27+ | Strong | Off study (breast cancer) | |
| 2 | F | 55 | A | 16 | 3 | 12 (PR) | Pom | 22+ | N/A | Off study (pneumonitis) | |
| 3 | M | 81 | AA | 41 | 3 | 9 (PR) | Obs | 22 | Yes | Intermed. | Off study (fatigue) |
| Dara/Dex (PR, 8 mo+) | |||||||||||
| 4 | M | 61 | W | 144 | 5 (+ASCT) | 10 (VGPR) | Obs | 12 | Yes | Strong | Off-study (hepatitis) |
| Dara/Pom/Dex (VGPR, 12 mo+) |
| Pt. no. . | Sex . | Age, y . | Race . | Months from Dx . | Lines of treatment, n . | Months on study . | Obs/Pom . | Remission from end of study, mo . | Relapse . | PD-L1* . | Therapy for PD . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| sCR | |||||||||||
| 1 | M | 66 | W | 38 | 3 (+ASCT) | 29 | Obs | 18+ | Strong | ||
| 2 | M | 63 | W | 56 | 3 (+ASCT) | 21 | Obs | 18+ | N/A | ||
| 3 | F | 57 | AA | 47 | 3 | 14 | Pom | 18+ | N/A | ||
| 4 | F | 57 | AA | 23 | 2 | 21 | Pom | 10 | Yes | Weak | Dara/Carf/Dex (PR, 8 mo), 2nd relapse—BCMA antibody conjugate |
| VGPR | |||||||||||
| 1 | M | 66 | AA | 145 | 4 | 27 | Pom | 18+ | Strong | ||
| 2 | F | 35 | AA | 60 | 3 (+ASCT) | 17 | Pom | 18+ | Weak | ||
| 3 | M | 50 | H | 80 | 3 (+ASCT) | 15 | Pom | 18+ | Intermed. | ||
| 4 | F | 83 | W | 307 | 4 (+ASCT) | 17 | Pom | 12 | Yes | Strong | Dara/Dex (VGPR 6, mo+) |
| 5 | F | 56 | AA | 35 | 3 | 30 | Pom | 1 | Yes | Strong | Dara/Pom/Dex (VGPR, 17 mo+) |
| PR | |||||||||||
| 1 | M | 67 | AA | 35 | 2 | 25 | Obs | 17+ | Intermed. | ||
| 2 | M | 60 | W | 42 | 2 (+ASCT) | 15 | Pom | 16 | Yes | Weak | Venetoclax/Dex (PR, 2 mo+) |
| 3 | M | 66 | W | 25 | 2 (+ASCT) | 12 | Obs | 6 | Yes | N/A | Dara/Len/Dex (PR,12 mo+) |
| Off study† | |||||||||||
| 1 | F | 65 | AA | 38 | 2 | 20 (sCR) | Obs | 27+ | Strong | Off study (breast cancer) | |
| 2 | F | 55 | A | 16 | 3 | 12 (PR) | Pom | 22+ | N/A | Off study (pneumonitis) | |
| 3 | M | 81 | AA | 41 | 3 | 9 (PR) | Obs | 22 | Yes | Intermed. | Off study (fatigue) |
| Dara/Dex (PR, 8 mo+) | |||||||||||
| 4 | M | 61 | W | 144 | 5 (+ASCT) | 10 (VGPR) | Obs | 12 | Yes | Strong | Off-study (hepatitis) |
| Dara/Pom/Dex (VGPR, 12 mo+) |
AA, African American; A, Asian; BCMA, B-cell maturation antigen; Carf, carfilzomib; Dara, daratumumab, Dex, dexamethasone; Dx, diagnosis; H, Hispanic; Intermed., intermediate; N/A, not available; Obs, observation; PD, progressive disease; Pom, pomalidomide; Pt, patient; M, male; F, female; W, white; +ASCT, had autologous stem cell transplant.
PD-L1 immune-histochemistry membranous staining.
Because of toxicity.